At ASCO 2024, Sandy Srinivas, MD, highlights several key prostate cancer trials. CHAARTED 2 showed improved radiographic progression-free survival (rPFS) with abiraterone plus cabazitaxel vs abiraterone alone but did not significantly impact current practices. The CYCLONE 2 trial on abemaciclib with abiraterone was disappointing because it did not show the expected benefits.
Despite the negative results from MAST on metformin in low-grade prostate cancer, the study emphasized the importance of evaluating common treatments. Quality-of-life improvements were noted in the PSMAfore and EMBARK trials, with lutetium-177–PSMA-617 and enzalutamide showing promising results.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Key Insights on New Prostate Cancer Data From ASCO 2024 - Medscape - Jun 07, 2024.
Comments